The Zacks Analyst Blog Highlights: Western Union, Mylan, Valeant Pharmaceuticals, Sanofi and Pfizer

For Immediate Release

Chicago, IL – February 9, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Western Union Co. ( WU - Analyst Report), Mylan, Inc. (MYL - Analyst Report), Valeant Pharmaceuticals ( VRX), Sanofi ( SNY - Analyst Report) and Pfizer, Inc. ( PFE - Analyst Report).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Wednesday’s Analyst Blog:

Western Union In Line, Ups Dividend

World’s leading money transfer company, Western Union Co. ( WU - Analyst Report) reported fourth quarter operating earnings of 40 cents per share, in line with the Zacks Consensus Estimate. Earnings per share, however, were up 5.3% year over year on the back of a strong margin improvement in its Global Business Payments unit and a lower share count.

Western Union’s revenues for the quarter were $1.4 billion, up 5% year over year, and in line with the Zacks Consensus Estimate. The year-over-year increase came on the back of 20% hike in foreign exchange revenues and 2% increase in transaction fee, and was partly offset by 10% decline in other revenues.

Full year 2011 total revenues came in at $5.5 billion, up 6% year over year, and led by higher transaction, foreign exchange and other revenues. Earnings per share also increased 11% year over year to $1.57.

Total expenses for the quarter increased 4% year over year to $1.1 billion due to a 12% hike in selling, general and administrative expense and 1% increase in cost of services.

Key Events in 4Q

• Completion of acquisition of TGBP, a leading specialist provider of international business payments, which would enhance Western Union’s position in small and medium enterprise (“SME”) business-to-business cross border payments. The company views this area as one offering key strategic growth.
• Completion of acquisition of Finint S.r.l., one of Western Union’s leading money transfer network agents in Europe.
• Western Union also signed a global prepaid and money transfer agreement with MasterCard, which will help it to globalize prepaid services and allow it to leverage MasterCard's world-class global electronic network.
• Launched prepaid cards in Europe.

Dividend Hike

With a robust performance all through the year 2011, the company decided to reward its shareholders with a greater dividend payout. Consequently, the company declared a 25% increase in quarterly dividend to 10 cents per share. The dividend will be paid on March 30, 2012 to shareholders of record as of March 16, 2012.

Our Take

We are very impressed with Western Union’s solid performance throughout 2011. The company surpassed its earnings outlook from the beginning of the year and delivered highest full-year revenue growth rate since 2008.

For the year 2012, Western Union is intent on developing three main areas. These include expanding the existing network and increasing focus on retaining and adding new customers to the consumer money transfer business; creating a digital infrastructure to drive its electronic channels business and developing the B2B segment apart from ensuring successful integration of the Travelex business.

Given the pace at which the company is aggressively making acquisitions, expanding its agent network and rolling out new products and services, we expect the company to evolve from a transaction-based to a truly customer-centric organization within a short span thus offering added convenience and more choice to its consumers.

Western Union currently retains a Zacks #1 Rank, which translates into a short-term ‘Buy’ rating. However, based on its strong fundamentals, we are maintaining our long-term “Outperform” recommendation on the shares.

Mylan Acquires 2 Generics

Mylan, Inc. (MYL - Analyst Report), one of the leading generic drug makers in the world, recently announced the acquisition of two generic dermatological products from Canadian company Valeant Pharmaceuticals ( VRX). Mylan acquired the authorized generic version of Valeant Pharma’s Efudex cream indicated for the treatment of multiple actinic or solar keratoses.

Second, Mylan has acquired the abbreviated new drug application (ANDA) for the generic version of Valeant Pharma’s topical acne treatment BenzaClin. Mylan had originally manufactured and marketed the generic version of BenzaClin through an agreement with Valeant.

Terms of the deal have been kept confidential. Valeant Pharma was required to divest these generic products as per the terms of its deal to acquire Dermik, the dermatology unit of Sanofi ( SNY - Analyst Report), which was completed in December of last year.

Recently, Mylan also received tentative approval to market its generic version of Pfizer, Inc.’s ( PFE - Analyst Report) blockbuster cholesterol drug Lipitor which lost exclusivity in late November 2011.

Our Recommendation

We currently have an Outperform long-term recommendation on Mylan. The shares carry a Zacks #3 Rank (short-term Hold rating).

Mylan is one of the leading players in the US generics market. The company holds immense potential as many blockbuster drugs have begun to go off-patent and many more will lose patent exclusivity in the next few years.

Moreover, we are encouraged by Mylan’s geographic reach and product depth along with a robust generic product pipeline. We believe the generic segment will post strong sales in 2012 benefiting from a slew of product launches already lined up.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

Read the full analyst report on WU

Read the full analyst report on MYL

Read the full analyst report on VRX

Read the full analyst report on SNY

Read the full analyst report on PFE